Prilenia
prilenia.com
Actively hiring
Drug Discovery
Neurology & CNS Therapeutics
As featured in
View 1 job
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Funding and backers
Team
11-50
employees, estimated range
Backers
1
Amplitude Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 19, 2024
New executive Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer · Nasdaq
2018
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Amplitude Ventures News
Prilenia eyes 2025 launch for Huntington's drug pridopidine
Prilenia Therapeutics is planning to file its Huntington's disease drug pridopidine in the EU shortly, after mixed results in a phase 3 trial.
Read more
Report
Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research
Read more
Report
Prilenia and Ferrer Announce First Participant Enrolled in the "PREVAiLS" Phase 3 Study of Pridopidine in ALS
Read more
Report
Prilenia Therapeutics B.V.
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Prilenia Therapeutics B.V. reflects the research output of authors from Prilenia Therapeutics B.V. who published articles in the 145 j
Read more
Report
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
NAARDEN, The Netherlands& WALTHAM, Mass.---- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disord
Read more
Report
Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, i...
Read more
Report
Prilenia Therapeutics: Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
Prilenia's global phase 3 trial in Huntington's Disease (PROOF-HD) has enrolled 120 patients on schedule reaching 25% of its target PROOF-HD is the most advanced clinical trial in HD assessing
Read more
Report
Tech stack
Technologies named in job postings at Prilenia over the last 12 months, by layer, with the share of postings for each.
Technologies in use
3
Postings analysed
2
Stack modernity
57/100
Databases
Oracle
Cloud & platforms
GCP
Developer tools
CAPA
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
82/100
Scaling fast
Open positions
1
1 opened / 3 closed in 30 days
Median time-to-fill
120 days
faster than 12% of the market
ATS activity
Every ~3 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Leadership
50% ▲
Operations
50% ▼
Activity Timeline
New location: United States
Oct 2026
Added Oracle to stack
Oct 2026
Added HIPAA to stack
Oct 2026
Added GDPR to stack
Oct 2026
Added CAPA to stack
Oct 2026
Added Microsoft Office to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Boston
Boston
United States
HQ
1 open roles 1 posted in 90 days 100% remote 10-50 est. staff
hires for Leadership
Jobs
≈ $159k – $286k per year (Estimated) • Remote (United States) • Full-Time • 12+ years exp • Boston
Oracle
DevOps
GCP
Cybersecurity
GDPR
HIPAA
CAPA
Apply